{
    "clinical_study": {
        "@rank": "4892", 
        "arm_group": [
            {
                "arm_group_label": "LEHEL multi-nutrients supplement", 
                "arm_group_type": "Experimental", 
                "description": "75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Received only oral hypoglycemic agents."
            }
        ], 
        "brief_summary": {
            "textblock": "Due to metabolic disorders and dietary restrictions, patients with diabetes may have\n      different degrees of malnutrition. The primary objective of this study is to investigate\n      whether supplementation of LEHEL, a multi-nutrients supplement, is capable to improve\n      metabolic parameters in patients  with type 2 diabetes."
        }, 
        "brief_title": "Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is diagnosed with type 2 diabetes mellitus according to the Chinese type 2\n             diabetes prevention guide 2010, diagnostic criteria are as follows:\n\n             (1) Diabetes symptoms\uff08polydipsia\u3001polyphagia, polyuria, weight loss\u3001skin\n             itching\u3001blurred vision and other acute metabolic network disorder that caused by high\n             blood sugar\uff09combined with random blood sugar  \u226511.1 OR, (2) fasting plasma glucose\n             (FPG) \u22657.0 OR, (3) 2 h blood sugar after oral glucose tolerance test (OGTT) \u226511.1;\n\n          -  Subject is between 18 and 75 years of age, inclusive.\n\n          -  Subject's BMI is >18.5 kg/m2 and <35 kg/m2.\n\n          -  If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid\n             medication or hormone therapy, subject has been on constant dosage for at least two\n             months prior to screening visit.\n\n        Exclusion Criteria:\n\n          -  Subject that is diagnosed as type 1 diabetes, gestational diabetes and other kinds of\n             diabetes expect type 2.\n\n          -  Subject that use exogenous insulin for glucose control.\n\n          -  Subject that has a history of diabetic ketoacidosis.\n\n          -  Subject that has mental disorder, cancer, cirrhosis, renal disease and hepatic\n             disease.\n\n          -  Subject that has had a significant cardiovascular event less than six months prior to\n             screening visit or has history of congestive heart failure.\n\n          -  Subject that has had operation less than six months prior to screening visit.\n\n          -  Subject that has taken/is currently taking any dietary supplements or medications\n             that could profoundly affect blood glucose during the past one month prior to\n             screening visit.\n\n          -  Subject is known to be allergic or intolerant to any ingredient found in the study\n             product."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "71", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940302", 
            "org_study_id": "SGU-03", 
            "secondary_id": "2012BAD33B10"
        }, 
        "intervention": {
            "arm_group_label": "LEHEL multi-nutrients supplement", 
            "description": "The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.", 
            "intervention_name": "LEHEL multi-nutrients supplement", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Malnutrition; Metabolic disorders", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shaoguan", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "512005"
                }, 
                "name": "Shaoguan University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Metabolic Control Before and After Supplementation With LEHEL in Patients With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Wenhua Ling, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Hemoglobin A1c (HbA1c) and lipids (Cholesterol, HDL-cholesterol, Triglycerides) at study entry and 12 weeks after dietary intervention", 
            "measure": "Metabolic Control", 
            "safety_issue": "No", 
            "time_frame": "Twelve weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940302"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Shaoguan University", 
        "sponsors": {
            "collaborator": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shaoguan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}